Alzheimer’s Competition Is Moving Into the Home
The most interesting biotech development of the last forty-eight hours is not a new mechanism in early discovery or a…
Author: Jane Aubrey
Jane Aubrey brings over a decade of experience as a clinical researcher to her reporting on drug development and regulatory pathways. At The Biotech Codex, she breaks down complex trial data and analyzes the pipeline strategies of both emerging biotechs and legacy pharma giants. Her coverage demystifies the arduous journey from bench to bedside, keeping industry professionals informed on the latest therapeutic breakthroughs.
Convenience Is Becoming Part of the Clinical Value Proposition
The most important biotech development of the last forty-eight hours is not another deal, a manufacturing expansion, or a platform…
AI Biotech Is Starting to Look Like a Real Business, Not Just a Thesis
Biotech investors have heard a decade of claims about how artificial intelligence would compress timelines, improve hit rates, and redesign…
The Data Are Early, but the Strategy Is Bold
In biotech, investors often overreact to early efficacy hints and underappreciate the strategy hiding underneath them. The more interesting July…
Vertex Is Buying More Than a Rare-Disease Asset
The most revealing life-sciences development of the last two days is not a trial readout or a regulatory letter. It…
Precision Medicine Still Runs on Unforgiving Proof Thresholds
Biotech investors often reserve their emotional energy for glamorous failures: breakthrough drugs that miss endpoints, gene-editing platforms that stumble, cell…
TREGZI Turns the Transplant Itself Into the Therapy
Orca Bio’s newly approved TREGZI matters because it points to a different kind of innovation. Instead of treating transplant complications…
Gene Editing Is Moving Into Childhood, and the System Is Not Ready
The most important feature of a curative therapy is not always its mechanism. Sometimes it is the age at which…
Precision Oncology Is Becoming a Diagnostics Discipline
A good deal of biotech storytelling still assumes that the decisive event is the drug itself: the molecule works, the…
The FDA Is Moving Upstream Into Factory Formation
For decades, the drug industry treated regulation and manufacturing as sequential problems. Companies developed an asset, built or secured production…
Biotech Buyers Are Paying for Cash-Flow Bridges, Not Just Science
The most revealing biotech deal of the past two days is not really a science-acquisition story at all. It is…